6292results about "Depsipeptides" patented technology

The invention relates to the technical field of biology, in particular to a verticillium dahliae virulence gene, a verticillium dahliae virulence protein and application. The invention discloses a verticillium dahliae virulence gene VdPHO23like. The verticillium dahliae virulence gene VdPHO23like comprises a polynucleotide sequence for coding an amino acid sequence of SEQ ID NO: 3. According to the invention, expression of the gene is inhibited in a targeted manner through an RNA interference mediated gene silencing technology so as to weaken virulence of pathogenic bacteria, and an efficient, specific and environment-friendly comprehensive prevention and control strategy is provided for verticillium wilt of crops such as cotton.

The invention relates to the field of prevention and treatment of plant filamentous fungal diseases, in particular to an application of a compound NSC-32 (N-[(5Z)-4-oxo-5-(phenylmethylidene-1, 3-thiazolidin-3-yl) pyridin-4-carboxamide) in prevention and treatment of magnaporthe oryzae, and a preparation method of the compound NSC-32 (N-[(5Z)-4-oxo-5-(phenylmethylidene-1, 3-thiazolidin-3-yl) pyridin-4-carboxamide). MoPex19 protein is used as a target spot, a compound NSC-32 is obtained through screening, and it is proved that the compound can inhibit growth of magnaporthe oryzae and reduce pathogenicity of the magnaporthe oryzae. In addition, the application object, the use method, the target specificity and the action mechanism of the compound NSC-32 are further explored, and a new green pesticide and a new thought are provided for preventing and treating the magnaporthe oryzae.

Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Notably, CAR constructs with an intracellular domain of FcεRIγ had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK / NK-92 cells.

The present invention relates to the field of lentiviral delivery. Specifically provided are a mutated vesicular virus envelope protein and the use thereof in lentiviral vector packaging.

The invention belongs to the field of prevention and treatment of tilletia controversa Kuhn, and particularly relates to a tilletia controversa Kuhn effect protein g16561 and application thereof. An amino acid sequence of the Tilletia controversa Kuhn effect protein is shown as SEQ ID NO: 2. The effect protein plays an important role in the process of inhibiting plant defense reaction, and has an interaction relationship with a wheat protein in the process of infecting wheat by Tilletia controversa Kuhn. According to the invention, the pathogenesis of Tilletia controversa Kuhn can be deeply researched, and the excavation of wheat disease-resistant genes and the cultivation of wheat disease-resistant varieties can be promoted.

Systems and methods for targeted gene modification, targeted insertion, perturbation of gene transcripts, and nucleic acid editing. Novel nucleic acid targeting systems comprise components of CRISPR systems and non-LTR retrotransposon elements.

The invention belongs to the technical field of biology, and discloses application of a mycoplasma hyopneumoniae Ebh GA protein in preparation of mycoplasma hyopneumoniae or a multi-combined vaccine containing the mycoplasma hyopneumoniae. The applicant screens out the Ebh GA protein with immunogenicity from the mycoplasma hyopneumoniae for the first time, the Ebh GA protein is shown in SEQ ID NO.7 and can be used as a mycoplasma hyopneumoniae subunit vaccine, and therefore the applicant screens out the protein with immunogenicity of other pathogenic bacteria at the same time and combines the protein with the protein into a quadruple subunit vaccine. The antigens of the obtained quadruple vaccine have a synergistic effect, and compared with a single dose, the quadruple vaccine can enhance the immune effect of the quadruple vaccine.

The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating infection of various pathogenic streptococci, as well as a molecular architecture design, application and the like. According to the invention, three immune antigens, namely an elongation factor Tu (Tuf), a molecular chaperone DnaK and an elongation factor G (fusA), are screened, and it is proved that fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by infection of different serotypes and different types of streptococci, have good immunogenicity, play roles in immune protection and effective prevention and treatment, and have good application prospects. The bacillus subtilis has the characteristics of broad-spectrum and high-efficiency prevention of streptococcus bacterial infection, and has a wide application prospect.

Described herein are programmable DNA proteolytic target chimera complexes that can be used both for the direct treatment of cancer by inhibiting biochemical pathways that are overexpressed in cancer cells, and for the indirect treatment of cancer by recruiting the E3 ligase complex to engage with a protein of interest or a mutant thereof and initiating proteolysis. Also described herein are methods of using the complexes in the treatment of cancer, as well as compositions comprising the complexes.

The invention discloses a fermentation method of recombinant bacillus subtilis for expressing vibrio parahaemolyticus outer membrane protein, which comprises the following steps: inoculating a recombinant bacillus subtilis strain into a liquid culture medium for activation and amplification to obtain a seed solution; transferring the seed solution into a fermentation tank according to the inoculum size of 5%-10%, controlling the temperature to be 35-37 DEG C and the pH to be 6.8-7.2, introducing sterile air and stirring, and monitoring the thallus concentration OD600 value in real time; when the OD600 value reaches 35-38, 10% of an inducer is added for pre-induction; when the OD600 value reaches 40-45, the remaining 90% of the inducer is added for main induction, and the real-time dissolved oxygen value is collected; when the real-time dissolved oxygen value is continuously higher than a first preset threshold value, the flow acceleration rate of the inducer is increased, the fermentation temperature is increased at the same time or step by step, and the increase amplitude of the dissolved oxygen value is in positive correlation with the flow acceleration rate and the temperature increase amplitude; when the OD600 value is stabilized in a preset interval, it is judged that fermentation is completed, and the recombinant bacillus subtilis thalli are obtained. The yield and quality of the vibrio parahaemolyticus outer membrane protein can be effectively improved.

This invention discloses a milk protein containing composition comprising: at least one milk protein; at least a first protein; at least a second protein; and at least a linker comprising an amino acid sequence coded by nucleotide sequence which is at least 80% similar to sequences selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21

The invention belongs to the technical field of immunotherapy, and particularly relates to a monkey pox virus antigen epitope peptide and application thereof. The invention aims to solve the technical problem that at present, a T cell antigen epitope peptide for universal vaccines of monkey pox viruses is not developed in the field of monkey pox viruses. According to the technical scheme of the invention, the amino acid sequence of the monkey pox virus antigen epitope peptide is shown as SEQ ID No.2. The antigen epitope peptide provided by the invention has very strong immunogenicity, and can induce antigen-specific CD8 + T cells; the antibody can be directly loaded to antigen presenting cells, can activate T cells and effectively induce T cell immunity, and can be used for research and development and preparation of universal vaccines for monkey pox viruses, research and development of drugs and clinical treatment.

The invention provides a mutant of enterovirus 71 and virus-like particles thereof, and relates to the field of biological medicines. The enterovirus 71 type virus-like particle is obtained by modifying structural genes VP0, VP1 and VP3 of virus capsid protein by utilizing computational structure biology and completing self-assembly in vivo through a hansenula polymorpha expression system. Compared with the unmodified enterovirus 71 type mutant and the virus-like particles thereof, the enterovirus 71 type mutant and the virus-like particles thereof have the advantages that the immunogenicity can be obviously improved, and the clinical application prospect is relatively high.

This disclosure provides nanoparticle compositions, and use thereof for isolating and measuring proteins, protein degrader action, and cells. The disclosed nanoparticles can be identified by barcodes that reveal the identity of and post translational modifications to the bound protein using image processing techniques described herein.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

Provided are an antibacterial peptide and the use thereof. The antibacterial peptide has a structure represented by formula (I), wherein Z1 is selected from tetrapeptides, the tetrapeptides being optionally modified by -OH, -CHO, -COOH, -NH2, -SO3H or -C=O; S1 and S2 are each independently selected from amino acids having the structure of (I); Q1 and Q2 are each independently selected from dipeptides or tripeptides; and n is independently selected from any integer between 1 and 6. (Q2)4-(S2-Q1)2-S1-Z1

The invention relates to mutant forms of CsgG. The invention also related to analyte detection and characterisation using CsgG.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention provides a plug-and-play Mi3 protein nanocage fusion protein with a VNP6 tag and a preparation method and application of the plug-and-play Mi3 protein nanocage fusion protein, the fusion protein comprises the VNP6 tag, a SpyCatch003 component, a Mi3 protein nanocage and a functional protein sequence, and the VNP6 tag is located at the N end of the fusion protein. The VNP6 peptide sequence or the variant thereof is utilized to induce a vesicle or vesicle-like structure beneficial to protein folding and stabilization in escherichia coli, so that the correct folding rate and activity of recombinant protein are improved while the overall intracellular molecular crowding effect is relieved. The core idea of the invention lies in that the internal structure of cells is regulated at low temperature, and the internal microenvironment of an escherichia coli expression system is optimized, so that protein molecules under high expression load can obtain more reasonable spatial distribution, and the problems of misfolding and aggregation caused by molecular crowding are reduced.

The invention belongs to the field of polypeptides, and particularly relates to an antibacterial peptide derived from marine microorganisms, an antibacterial composition and application. Based on a deep learning algorithm, five potential antibacterial peptides are mined from a global marine microbiome database, and the five antibacterial peptides are expressed in yarrowia lipolytica. Experimental tests show that the five antibacterial peptides have differentiated antibacterial effects on different bacteria, and the antibacterial peptide shown in SEQ ID NO: 3 can have an obvious inhibition effect on escherichia coli, pseudomonas aeruginosa and staphylococcus aureus, has low hemolysis and has a positive application prospect. The antibacterial peptide disclosed by the invention has the potential of further developing novel antibacterial drugs or antibacterial additives.

The invention belongs to the field of genetic engineering and resource recycling, and relates to a ferrous oxide recombinant bacterium, a recombination method and application of the ferrous oxide recombinant bacterium in lithium battery metal recovery. The ferrous oxide recombinant bacterium is obtained by taking thiobacillus ferrooxidans as an original strain through genetic engineering modification; comprising thiobacillus ferrooxidans, an exogenously introduced nickel / cobalt efflux protein RcnA gene, a vector pJRD215 and donor bacteria, and the nickel / cobalt efflux protein RcnA gene is introduced into the vector pJRD215, driven to express and then introduced into the donor bacteria to express. The application of the constructed and prepared ferrous oxide recombinant bacteria in lithium battery metal recovery is used for improving the leaching efficiency of metal ions Co < + > or / and Li < + > or / and Ni < + > in lithium battery powder; and the method shows good adaptability and stability under different substrate concentrations, and provides a key experimental support and an important experimental basis for application of a microbial enhanced leaching technology in the field of waste lithium battery resource utilization.

Compositions of retroviruses and methods of using the same for gene delivery, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non-viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.

The invention provides a bovine parainfluenza virus type 3 QL3 strain, and the preservation number of the bovine parainfluenza virus type 3 QL3 strain is CGMCC No.46469. The invention also provides a bovine parainfluenza inactivated vaccine containing the bovine parainfluenza virus type 3 QL3 strain and purified F protein and HN protein of the QL3 strain. The novel bovine parainfluenza virus type 3 inactivated vaccine is obtained by optimizing the antigen components of the bovine parainfluenza virus type 3 inactivated vaccine, and high-level neutralizing antibodies can be generated after immunizing cattle; the safety of the vaccine is improved through process optimization. Safety and potency test results show that after the inactivated vaccine is used for immunizing cattle, no adverse reaction exists, and high-level neutralizing antibodies are generated. Results show that the immune effect of the bovine parainfluenza virus type 3 inactivated vaccine can be improved.

The invention belongs to the technical field of preparation of polypeptides, and particularly relates to a self-assembled polypeptide capable of responding to alkaline phosphatase and degrading Neuropilin-1 as well as a preparation method and application of the self-assembled polypeptide. The self-assembled polypeptide (formula I) provided by the invention has a self-assembly starting unit 'GNNQQNY (SEQ ID NO: 1)', can be self-assembled in vitro, and can form nanofibers after responding to alkaline phosphatase, so that not only can the critical self-assembly concentration of the polypeptide be reduced, but also the binding capacity with target protein can be improved. The material can degrade NRP1 on the surfaces of tumor cells and Treg cells, and has huge potential in promoting immunotherapy of tumors.

The invention provides a recombinant chicken antibacterial peptide aiming at drug-resistant staphylococcus aureus, and belongs to the technical field of veterinarians. The recombinant chicken antibacterial peptide is expressed through genetic engineering recombinant escherichia coli. Three natural chicken antibacterial peptide active regions are fused, and two disulfide bonds are introduced to stabilize the structure of the recombinant chicken antibacterial peptide and enhance the affinity of the recombinant chicken antibacterial peptide to staphylococcus aureus outer membrane protein. The minimum inhibitory concentration of the recombinant chicken antibacterial peptide to the drug-resistant staphylococcus aureus is obviously lower than that of three natural chicken antibacterial peptides, and the formation of a biomembrane of a USA300 strain of the drug-resistant staphylococcus aureus can be thoroughly inhibited when the minimum inhibitory concentration is 8 mu g / mL. The recombinant chicken antibacterial peptide has a good antibacterial effect on different drug-resistant staphylococcus aureus separated from a chicken house, and can effectively solve the infection problem of the drug-resistant staphylococcus aureus in the chicken house.

Provided herein are compositions and methods for use in challenging pathogenic bacteria on plants. Optional features include modification of a donor bacteria to include exogenous nucleic acids encoding for conjugation machinery and gene modification components, such as guide sequence for use in CRISPR. The compositions and methods provided herein can be used for delivery to a wide variety of crops and for targeting one or more pathogens.

Chimeric antigen receptors that include an antigen recognition domain; a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR; and an intracellular signaling domain.

The invention relates to a complement C9 mini binding protein or a mutant thereof and application thereof. The complement C9 mini binding protein of the present application comprises an amino acid sequence selected from the group consisting of SEQ ID No. 6 to SEQ ID No. 65. Tests prove that the complement C9 mini-binding protein shows an excellent hemolysis inhibition effect, and the complement C9 mini-binding protein is remarkably superior to ecubezumab in the aspects of thermal stability of the protein, acute hemolysis inhibition and the like. Therefore, a series of complement C9 mini-binding proteins developed by the application have wide application prospects in development of drugs for treating diseases related to complement C9-mediated intravascular hemolysis.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.